Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America
Posted: February 5, 2025 at 2:42 am
Ghent, Belgium, 4th February 2025
Read more here:
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America
Posted in Global News Feed
Comments Off on Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America
Iantrek Appoints Adam Szaronos as Chief Executive Officer
Posted: February 5, 2025 at 2:42 am
WHITE PLAINS, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical technology company pioneering bio-interventional approaches for chronic eye diseases, today announced the appointment of Adam Szaronos, as its new Chief Executive Officer. Mr. Szaronos succeeds company founder and innovator Sean Ianchulev, MD, MPH who will remain as Chairman of the Board and Chief Medical Officer.
The rest is here:
Iantrek Appoints Adam Szaronos as Chief Executive Officer
Posted in Global News Feed
Comments Off on Iantrek Appoints Adam Szaronos as Chief Executive Officer
Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC
Posted: February 5, 2025 at 2:42 am
SportsGel will feature a sports-specific range of products available for license, with first deal to launch in China in H1 2025 SportsGel will feature a sports-specific range of products available for license, with first deal to launch in China in H1 2025
Here is the original post:
Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC
Posted in Global News Feed
Comments Off on Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer…
Posted: February 5, 2025 at 2:42 am
– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 –
Posted in Global News Feed
Comments Off on IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer…
Allogene Therapeutics Announces Participation in February Investor Conferences
Posted: February 5, 2025 at 2:42 am
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in February.
Continued here:
Allogene Therapeutics Announces Participation in February Investor Conferences
Posted in Global News Feed
Comments Off on Allogene Therapeutics Announces Participation in February Investor Conferences
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Posted: February 5, 2025 at 2:42 am
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, 2025 at 8:00 AM ET. To attend the virtual fireside chat, please register here.
Continued here:
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Posted in Global News Feed
Comments Off on MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI
Posted: February 5, 2025 at 2:42 am
Now available on the AISight® Platform, PathAssist Derm is an AI-assisted histopathology tool that enhances dermatopathology research workflows, accelerating skin cancer research
Continued here:
PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI
Posted in Global News Feed
Comments Off on PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Posted: February 5, 2025 at 2:42 am
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 12:00 pm – 12:30 pm ET.
Read the original post:
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Posted in Global News Feed
Comments Off on Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
Posted: February 5, 2025 at 2:42 am
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations, including the status of its program, resources, and capabilities. The Company has made the determination to discontinue all clinical studies evaluating TIDAL-01 and halt further development of the program. As a result, Turnstone’s management and its Board of Directors have initiated a process to explore and review strategic alternatives focused on maximizing shareholder value.
Read more:
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
Posted in Global News Feed
Comments Off on Turnstone Biologics Announces Plans to Explore Strategic Alternatives
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Posted: February 5, 2025 at 2:42 am
Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today a patent publication by the Instituto Mexicano de la Propriedad Industrial (IMPI), the National Mexico Patent Office. The patent refers to the Company’s innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
Go here to see the original:
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Posted in Global News Feed
Comments Off on Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
